DOI QR코드

DOI QR Code

Retrospective Analysis of Neoadjuvant Chemotherapy for Breast Cancer in Turkish Patients

  • Duman, Berna Bozkurt (Adana Training and Research Hospital, Department of Oncology) ;
  • Afsar, Cigdem Usul (Cukurova University Medical Faculty, Department of Medical Oncology) ;
  • Gunaldi, Meral (Cukurova University Medical Faculty, Department of Medical Oncology) ;
  • Sahin, Berksoy (Cukurova University Medical Faculty, Department of Medical Oncology) ;
  • Kara, I. Oguz (Cukurova University Medical Faculty, Department of Medical Oncology) ;
  • Erkisi, Melek (Cukurova University Medical Faculty, Department of Medical Oncology) ;
  • Ercolak, Vehbi (Cukurova University Medical Faculty, Department of Medical Oncology)
  • 발행 : 2012.08.31

초록

Background: Neoadjuvant systemic chemotherapy is the accepted approach for women with locally advanced breast cancer. Anthracycline- and taxane-based regimens have been extensively studied in clinical trials and consequently are widely used. In this study aimed to research the complete response (pCR) rates in different regimens for neoadjuvant setting and determine associated clinical and biological factors. Methods: This study included 63 patients diagnosed with breast carcinoma among 95 patients that had been treated with neoadjuvant chemotherapy between 2007 and 2010. TNM staging system was used for staging. The histologic response to neoadjuvant chemotherapy was characterized as a pCR when there was no evidence of residual invasive tumor in the breast or axillary lymph nodes. Biologic subclassification using estrogen receptor (ER), progesterone receptor (PR), HER2 were performed. Luminal A was defined as ER+, PR+, HER2-; Luminal B tumor was defined as ER+, PR-, HER2-; ER+, PR-, HER2+; ER-, PR+, HER2-; ER+, PR+, HER2+; HER2 like tumor ER-, PR+, HER2+; and triple negative tumor ER, PR, HER2 negative. Results: Patients median age was 54.14 (min-max: 30-75). Thirty-two patients (50.8%) were premenapousal and 31 (49.2%) were postmenapousal. Staging was performed postoperatively based on the pathology report and appropriated imaging modalities The TNM (tumor, lymph node, metastasis) system was used for clinical and pathological staging. Fifty-seven (90.5%) were invasive ductal carcinomas, 6 (9.5%) were other subtypes. Thirty nine (61.9%) were grade II and 24 (38.1%) were grade III. Seven (11.1%) patients were stage II and 56 (88.9) patients were stage III. The patients were classified for ER, PR receptor and HER2 positivity. Seventeen patients had complete response to chemotherapy. Forty patients (63.5%) were treated with dose dense regimen (cyclophosphamide 600 mg/m2 and doxorubicine 60 mg/m every two weeks than paclitaxel 175 mg/m2 every two weeks with filgrastim support) 40 patients (48%) were treated anthracycline and taxane containing regimens. Thirteen patients (76%) from 17 patients with pCR were treated with the dose dense regimen but without statistical significance (p=0.06). pCR was higher in HER2(-), ER(-), grade III, premenopausal patients. Conclusion: pCR rate was higher in the group that treated with dose dense regimen, which should thus be the selected regimen in neoadjuvant setting. Some other factors can predict pCR in Turkish patients, like grade, menopausal status, triple negativity, percentage of ER positivity, and HER2 expression.

키워드

Breast cancer;neoadjuvant chemotherapy;ER;PR;HER2;grade;Turkish patients

참고문헌

  1. Baselga J, Bradbury I, Eidtmann H, et al (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 18, 633-40.
  2. Bear HD Anderson S, Smith RE, Geyer CE Jr, et al (2006). Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 24, 2019-27. https://doi.org/10.1200/JCO.2005.04.1665
  3. Burstein HJ, Harris LN, Marcom PK, et al (2003). Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol, 21, 2889-95. https://doi.org/10.1200/JCO.2003.02.018
  4. Buzdar AU, Ibrahim NK, Francis D, et al (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol, 23, 3676-85. https://doi.org/10.1200/JCO.2005.07.032
  5. Buzdar AU, Singletary SE, Theriault RL, et al (1999). Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol, 17, 3412-7. https://doi.org/10.1200/JCO.1999.17.11.3412
  6. Citron ML, Berry DA, Cirrincione C, et al (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 21, 1431. https://doi.org/10.1200/JCO.2003.09.081
  7. Coudert BP, Arnould L, Moreau L, et al (2006). Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol, 17, 409-14. https://doi.org/10.1093/annonc/mdj096
  8. Diéras V, Fumoleau P, Romieu G, et al (2004). Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol, 22, 4958-65. https://doi.org/10.1200/JCO.2004.02.122
  9. Evans TR, Yellowlees A, Foster E, et al (2005). Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol, 23, 2988- 95. https://doi.org/10.1200/JCO.2005.06.156
  10. Gianni L, Eiermann W, Semiglazov V, et al (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375, 377-84. https://doi.org/10.1016/S0140-6736(09)61964-4
  11. Gralow JR, Burstein HJ, Wood W, et al (2008). Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol, 26, 814. https://doi.org/10.1200/JCO.2007.15.3510
  12. Harris LN, You F, Schnitt SJ, (2007). Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res, 13, 1198-207. https://doi.org/10.1158/1078-0432.CCR-06-1304
  13. Huober J, von Minckwitz G, Denkert C, (2010). Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat, 124, 133-40. https://doi.org/10.1007/s10549-010-1103-9
  14. Hurley J, Doliny P, Reis I, et al (2006). Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol, 24, 1831-8. https://doi.org/10.1200/JCO.2005.02.8886
  15. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al (2006). Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol, 24, 1940. https://doi.org/10.1200/JCO.2005.02.6187
  16. Kuerer HM, Newman LA, Smith TL, (1999). Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J Clin Oncol, 17, 460-9 https://doi.org/10.1200/JCO.1999.17.2.460
  17. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D (2007). Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol, 25, 1232-8. https://doi.org/10.1200/JCO.2005.05.3306
  18. Moliterni A, Mansutti M, Aldrighetti D, et al (2007). Anthracycline-based sequential adjuvant chemotherapy in operable breast cancer: Five-year results of a randomized study by the Michelangelo Foundation. J Clin Oncol, 25, 18.
  19. Schwartz GF, Hortobagyi GN (2004). Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer, 100, 2512. https://doi.org/10.1002/cncr.20298
  20. Shannon C, Smith I (2003). Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol, 45, 77. https://doi.org/10.1016/S1040-8428(02)00091-4
  21. Sikov WM, Dizon DS, Strenger R, et al (2009). Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol, 27, 4693-700. https://doi.org/10.1200/JCO.2008.21.4163
  22. Smith IC, Heys SD, Hutcheon AW, et al (2002). Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol, 20, 1456-66. https://doi.org/10.1200/JCO.20.6.1456
  23. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al (2003). Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a doseintensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol, 21, 843. https://doi.org/10.1200/JCO.2003.05.135
  24. Untch M, Fasching PA, Konecny GE, et al (2011). Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol, 29, 3351-7. https://doi.org/10.1200/JCO.2010.31.4930
  25. Untch M, Loibl S, Bischoff J, et al (2012). Lapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane- based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol, 13, 135-44. https://doi.org/10.1016/S1470-2045(11)70397-7
  26. Untch M, Rezai M, Loibl S, et al (2010). Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 20, 2024-31.
  27. von Minckwitz G, Kümmel S, Vogel P, et al (2008). German Breast GroupNeoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst, 100, 542-51. https://doi.org/10.1093/jnci/djn085
  28. von Minckwitz G, Raab G, Caputo A, et al (2005). Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol, 23, 2676. https://doi.org/10.1200/JCO.2005.05.078

피인용 문헌

  1. Long-Term Survival of Women with Locally Advanced Breast Cancer with ≥10 Involved Lymph Nodes at Diagnosis vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3435
  2. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population vol.31, pp.9, 2014, https://doi.org/10.1007/s12032-014-0165-7
  3. Comparing Role of Two Chemotherapy Regimens, CMF and Anthracycline-Based, on Breast Cancer Survival in the Eastern Mediterranean Region and Asia by Multivariate Mixed Effects Models: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5655